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ABSTRACT 
By reaction of 2-aminofluorene with 2-pyridinecarboxaldehyde a new Schiff base (L) is 
obtained. The reaction of this ligand with Ag(I) and Cu(I) salts in different stoichiometry 
leads to the complexes [Ag(CF3SO3)(L)PPh3] (1) or [ML2]A (M = Ag, Cu; A = CF3SO3, 
ClO4 or BF4). Structural characterization by X-ray crystallography has been carried out for 
complexes [AgL2]ClO4 (4) and [Ag(L)(PPh3)2](CF3SO3) (6), which confirms the chelate 
nature of L and the presence of Ag···H interactions between two molecules. The biological 
studies show that Schiff base L presents antibacterial activity in Gram-positive bacteria and 
E. coli. The coordination to silver increases this activity, but the formation of the copper 
complex does not generate significant changes. 
1. Introduction 
Infectious diseases are a leading cause of death worldwide, and the mounting emergence of 
antibacterial resistance has contributed to rising rates of potentially-fatal infections. The 
bacteria implicated in these infections include the so-called ESKAPE pathogens, such as 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and various Enterobacter species [1,2]. 
Traditionally, development of new antibacterial molecules has been based mainly on two 
strategies: a) modifying or adding a small chemical group to an antibiotic already in clinical 
use, to improve some aspect of its pharmacodynamic and/or pharmacokinetic profile; or b) 
seeking new molecules from natural products that have demonstrated activity against 
resistant bacteria. Both strategies involve structural modifications or additions that preserve 
the pharmacophore and therefore maintain both the mechanism and site of action. 
  
Optimizing these compounds may be effective initially; however, due to the structural 
similarity of the novel and existing molecules, bacteria rapidly adapt their resistance 
mechanisms to thwart the new antibiotics [3]. 
New approaches should consider novel structures, no present in microorganisms. In this 
regard, the Schiff bases and their metal complexes play an important role in the 
bioinorganic chemistry due to their structural diversity and wide spectrum of their 
biological activities. A number of copper and silver complexes with Schiff bases have been 
already studied for antibacterial activity [4-14]. Actually, there is not a drug that 
incorporates a copper in their structure, but is available only one product with silver, silver 
sulfadiazine (SSD). The principal problem with SSD is a poor solubility, which is the 
reason because is presented in topical formulations. 
The redox properties of copper can cause cellular damage. A number or mechanisms have 
been suggested. Reactive hydroxyl radicals can be generated in a Fenton-type reaction. The 
extremely reactive hydroxyl radical can participate in a number of reactions detrimental to 
cellular molecules, such as the oxidation of proteins and lipids [15]. Copper ions can also 
lead to depletion of sulfhydryls, such as in cysteines or glutathione. The hydrogen peroxide 
thus generated can in turn participate in redox reaction and lead to further generation of 
toxic hydroxyl radicals. 
Silver has been known to possess antimicrobial properties for more than two thousand 
years and is considered a broad-spectrum antimicrobial agent [16]. It is well established 
that metallic silver causes minimum damage to a living organism and cationic Ag+ is the 
biologically active species in applications of silver-containing compounds [16]. The 
antimicrobial properties of Ag+ are mainly attributed to its ability to bind thiols on proteins 
and enzymes, block cellular respiration, cause cell membrane damage [16], and bind to 
nucleic acids [17]. In addition to silver salts, silver complexes derived from various ligands 
have regained attention as antimicrobial agents [18]. 
The structural versatility of the Schiff bases permits pharmacokinetic control to improve 
and the solubility of new compounds, and together with the known capacity to coordinate 
metals like copper and silver, with potent antibacterial activity, suggest that this compounds 
can give a new kind of antimicrobial drugs with interesting properties. Here we report the 
synthesis of a new kind of Schiff base and its complexes with copper and silver, that are 
water soluble and with high antibacterial activity. 
2. Results and discussion 
The preparation of the Schiff base L has been achieved, in good yield, by reaction of 2-
aminofluorene with 2-pyridinecarboxaldehyde in a 2:1 ratio in the presence of glacial acetic 
acid. In the FT-IR spectrum the vibration (C=N)iminic = 1625, (C=N)py = 1599 (cm
-1). The 
  
resonances for 1H and 13C{1H} NMR spectra agree with the proposed formulation (see 
Experimental section). 
The coordination behavior of this ligand towards Ag(I) and Cu(I) compounds has been 
studied. In first place, the reaction of L with [Ag(CF3SO3)PPh3] leads to complex 1 in 
which the binding of the silver fragment to the two N groups is proposed (see Scheme 1). 
In the FT-IR spectrum the vibrations (C=N)iminic and (C=N)py  appear at 1601 and 1587 
cm-1, respectively. The presence of triflate and triphenylphosphine is confirmed by the 
corresponding bands due to these groups (see Experimental section). The 19F spectrum 
shows one signal at - 80.07 ppm and the 31P{H} shows a singlet at 11.68 ppm. In the 1H 
NMR spectra it is observed that the displacements of the CH groups attached to the 
nitrogen are shifted downfield by the coordination of the metal. The ratio L/PPh3 is 1/1. 
 
 
Scheme 1. Synthesis of the silver and copper complexes with the Schiff base L. 
 
The reaction of L with AgA (A = CF3SO3, ClO4 or BF4) in a 2:1 ratio gives the complexes 
[AgL2]A (2-4) as yellow solids in good yield. In the 
1H and 13C NMR spectra, all signals 
corresponding to the ligand L are observed with a different chemical shift, and it is possible 
to see that the protons of the CH groups attached to the nitrogen undergo downfield 
displacements, due to the coordination of silver. In the fluorine NMR spectrum the signal 
  
for the triflate (2) and BF4
- (4) anions appears at – 80.06 and – 153.37 ppm, respectively. 
The presence of the base L and the anions CF3SO3 
– (2), ClO4
- (3) or BF4
-
 (4) is confirmed 
in the FT-IR spectra by the corresponding bands due to these groups (see Experimental 
section). 
The coordination behavior of L towards copper(I) is similar and the reaction with 
[Cu(CH3CN)4]BF4 (molar ratio 2:1) leads to [CuL2]BF4 (5). The FT-IR, 
1H, 19F, and 13C 
NMR spectra are very similar to that of the silver complex 4. 
The crystal structure of complex 4 has been established by X-ray diffraction studies, and 
the cation can be seen in Figure 1. The silver center is found in a tetrahedral geometry 
bonded to two Schiff base ligands in an N^N chelate fashion. The two planar ligands are 
located almost perpendicular one to each other. The Ag-N distances lye in the range Ag1 
N4 2.2928(17) to Ag1 N3 2.386(2) Å, which belongs to the two nitrogen atoms of one of 
the ligands. The bite angles of the ligands coordinated to the silver atom are quite narrow, 
N1 Ag1 N2 72.63(6), N4 Ag1 N3 72.86(7), and this causes the distorsion from the ideal 
tetrahedral geometry. 
 
Figure 1. Molecular structure of the cation of complex 4. H atoms are omitted for clarity. Selected bond 
lengths (Å) and angles (º): Ag1 N4 2.2928(17), Ag1 N1 2.3008(18), Ag1 N2 2.3482(18), Ag1 N3 2.386(2), 
N1 C1 1.331(3), N1 C5 1.355(3), N2 C6 1.274(3), N2 C7 1.418(3), N3 C20 1.333(3), N3 C24 1.345(3), N4 
C25 1.273(3), N4 C26 1.425(3); N4 Ag1 N1 134.38(6), N4 Ag1 N2 141.74(6), N1 Ag1 N2 72.63(6), N4 Ag1 
N3 72.86(7), N1 Ag1 N3 133.62(6), N2 Ag1 N3 109.79(7). 
In the crystal of compound 4 several secondary interactions are observed between two 
adjacent molecules, originated by the hydrogen bonding between some of the hydrogen of 
the fluorene moiety of one molecule and the silver center of the other molecule, with 
distances Ag(1)···H(19) 2.761,  Ag(1)···H(38) 2.777, Ag(1)···H(29) 2.818 Å (Figure 2).   
  
 
Figure 2. Ag···H hydrogen bonding in complex 4. 
When [Ag(CF3SO3)(L)(PPh3)] (1) was recrystallized, by slow diffusion of diethyl ether into 
a dichloromethane solution, suitable crystals for X-ray diffraction of the complex with two 
phosphines, [Ag(L)(PPh3)2](CF3SO3) (6), was obtained, see Figure 3. The complex 
crystallizes with two independent molecules per asymmetric unit. The silver center is found 
in a tetrahedral geometry bonded to the chelate ligand and to two phosphine moieties. The 
Ag- N bond lengths are Ag1-N2 2.316(3) and Ag1-N1 2.366(3), which are similar to those 
found in complex 4. The Ag-P distances Ag-P2 2.4274(10) and Ag1-P1 2.4350(10) are also 
normal for these type of compounds. The bite angle of the Schiff base ligand  
 
Figure 3. Molecular structure of the cation of complex 6. Hydrogen atoms are omitted for clarity. Selected 
bond lengths (Å) and angles (º): Ag1 N2 2.316(3), Ag1 N1 2.366(3), Ag P2 2.4274(10), Ag1 P1 2.4350(10); 
N2 Ag1 N1 71.54(9), N2 Ag1 P2 115.57(7), N1 Ag1 P2 119.47(6), N2 Ag1 P1 117.28(7), N1 Ag1 P1 
109.16(7), P2 Ag1 P1 116.21(4). 
2.1. Biological studies 
The results of screening for antibacterial activity are shown in Table 1 
  
Table 1: Antibacterial Activity results. 
 MIC (µg/mL) 
Compound MSSA MRSA E. faecalis E.coli P.aeruginosa K.pneumoniae 
L 256 256 256 256 >256 >256 
1 8 8 8 8 8 32 
2 64 64 64 16 16 32 
3 64 64 64 8 16 32 
4 64 64 32 8 16 32 
5 256 256 256 256 256 >256 
vancomycin 1 1 2 - - - 
gentamicin - - - 0.5 1 2 
 
The results show that the L ligand has antibacterial activity in bacteria MSSA, MRSA, E. 
faecalis and in E. coli at 256 μg/mL, nevertheless, no activity was observed in P. 
aeruginosa and K. pneumoniae. The compounds 1-4 have good activity against all bacteria 
studied, were 1 present the highest activity of the silver complexes group. Compound 5 
(copper complex) have a MIC of 256 μg/mL in five of the bacteria, except in K. 
pneumoniae where is inactive. 
The ligand L is common in all the complexes 1-5, and shows a week activity in 
antibacterial screening. However, when L is complexed with silver to get compound 1, the 
activity increases significatively, but the addition of a second L ligand reduce the 
antibacterial activity 2 or 8 times (compounds 2-4). Into the compounds constituted with 
two L and silver atom; we found different activities depending on the counterion. In 
comparison with compound 1, the activity against Gram-positive bacteria of complexes 2 
and 4 is reduced 4-8 times, however, in Gram-negative bacteria the antibacterial effect 
down only two times. Interestingly, the MIC value for compound 4 against E. coli does not 
change respect to 1. Comparing compound 1 with 2, the main structural difference is the 
change of the ligand PPh3 for L and that produce a fall in activity from 8 to 64 μg/mL. The 
bactericidal activity of silver compounds can be attributed to two different properties, first, 
the ability to generate ROS and second their affinity to associate closely with R-SH groups. 
The silver ions can easily bind to SH groups, such as in cysteine, which can directly disrupt 
the function of specific enzymes or break S–S bridges necessary to maintain the integrity of 
folded proteins, causing detrimental effects to the metabolism and physiology of the cell 
[19]. The bind to SH groups requires a silver ion-free or available to react; this can explain 
the highest activity of 1 compared with 2-4. In 1, the silver atom has less steric hindrance 
than compounds 2-4. The two L ligands surround the silver ion hamper the reaction with 
SH groups. It is interesting to observe that the replacement of the silver atom by copper, 
decrease the activity dramatically (compare compound 4 and 5 in Table 1). The differences 
in the antimicrobial potency of silver and copper ions can be explained by the cysteine 
  
affinity and homeostasis. The copper ions have a higher affinity to cysteine as compared to 
silver ions [20]. However, the difference in the activity of the copper or silver ions could be 
based in the fact that copper is an essential element and cells possess mechanisms to 
maintain its homeostasis by avoiding its intracellular toxicity. On the other hand, silver ion 
is not an essential element and, by irreversibly binding the cysteines, it can poison vital 
enzymatic systems, such as the main energy source of the cells or the respiratory electron 
transport chains. 
3. Conclusions 
A Schiff base derived from 2-aminofluorene has been prepared and the coordination 
behavior of this new ligand towards silver and copper salts has been studied. Coordination 
through the two nitrogen atoms to the metals is proposed for all the complexes and 
confirmed by X-ray diffraction for two of them, thus the chelate nature of the Schiff base L 
has been corroborated in the structure of [Ag(L)2](ClO4) (4) or in [Ag(L)(PPh3)2](CF3SO3) 
(6), obtained in the crystallization of 1. In addition Ag···H hydrogen bonding interactions 
are found between two molecules of compound 4. 
The biological studies show that L presents negligible antibacterial activity in Gram-
positive bacteria (MSSA, MRSA, and E. faecalis) and E. coli at 256 μg/mL. However, the 
formation of silver complexes generate active compounds in all evaluated bacteria, with 
marked differences in antibacterial activity with increases up to 32-fold when compared to 
L. The formation of a copper complex does not generate significant changes in antibacterial 
activity, since it retain the MIC value of L in MSSA, MRSA, E. faecalis, and E. coli and 
only slightly improving the activity in P. aeruginosa (MIC = 256 μg / mL). This compound 
had no activity in K. Pneumoniae. 
4. Experimental  
4.1. General information 
1H and 13C{1H} NMR spectra were recorded at room temperature on a BRUKER 
AVANCE 400 spectrometer (1H, 400 MHz, 13C, 100.6 MHz). 2-aminofluorene and 2-
pyridinecarboxaldehyde were obtained from Aldrich and were used without further 
purification. 
4.2. Synthesis of the Schiff Base L 
To a solution of 2-aminofluorene (0.568 g, 3.15 mmol) in 20 ml of CHCl3, 2-
pyridinecarboxaldehyde (0.200 g, 1.88 mmol) in CHCl3 (10 mL) and glacial acetic acid 
(0.6 mL) were added and the mixture was stirred  for  8 days at refluxing temperature and 
protected from light. Afterwards the solution was evaporated under reduced pressure and 
the solid was washed with diethyl ether and n-hexane; a yellow solid was obtained, (Yield 
81.4%). FT-IR (cm-1): (C=N)iminic = 1625, (C=N)py = 1599. 
1H NMR (acetone-d6)  
  
(ppm): 8.70 (ddd, H17, J = 4,8 Hz,1H), 8.68 (m, H22, 1H), 8.24 (dt, H19, J = 7.9 Hz, 1H), 
7.91 (m, H20,5,10, 3H), 7.57 (m, H2,18, 2H), 7.38-7.28 (m, H4,11,12,13, 4H), 3.95 (s, H23,24, 2H). 
13C APT–NMR (acetone-d6)   (ppm): 160.85 (C21), 155.85 (C15), 150.85 (C3), 150.61 
(C17), 145.56  (C8), 144.61  (C1), 142.05 (C7), 141.45 (C6), 137.61 (C19), 127.76 (C18), 
126.14 (C12,13,11), 121.87 (C20), 121.47 (C10), 121.33 (C4),120.74 (C2), 118.72 (C5), 37.44 
(C9). 
4.3. Synthesis of the complexes 1-5 
To a solution of 0.5 mmol of [Ag(CF3SO3)PPh3] (0.259 g), Ag(CF3SO3) (0.128 g), 
Ag(ClO4) (0.103 g), Ag(BF4) (0.097 g), or [Cu(CH3CN)4]BF4 (0.57 g) in 20 mL of acetone 
(2), dichloromethane (1, 3 or 4)  or ethanol (5), a stoichiometric amount of the Schiff base 
L (0,135 g, 0.5 mmol) was added. The mixture was stirred at room temperature for 1 hour 
and it was protected from light. The solution was evaporated under reduced pressure to a 
small volume (3 mL). The solid was washed with diethyl ether and n-hexane: 
[Ag(CF3SO3)(L)PPh3] (1) was isolated as a yellow solid, 94.3 % yield. FT-IR (cm
-1): 
(C=N)imínic = 1601; (C-N)py = 1587; (CF3SO3) = 1261, 1140, 1039, 562, 506; (PPh3) = 
1086, 697, 641.  19F NMR (acetone-d6),  (ppm): - 80.07 (s). 31P{H} NMR (acetone-d6), δ 
(ppm): 11.68 (s); 1H NMR (acetone-d6), δ (ppm): 9,00 (s, H22, 1H); 8.77 (dd, H17,  J = 3.5 
Hz, 1H); 8.25  (dt, H19, J = 7,8 Hz, 1H); 8.15 (td, H20, J = 7.7 Hz, 1H); 7,90 (d, H5,10, J = 
7,8 Hz, 2H); 7.61 (m, H2,18, J = 7,6 Hz, 2H); 7.50 (m, H4,11,12,13, 4H); 7.37 (m, PPh3, 15H); 
3.71 (s, H23,24, 2H).
13C-APT NMR (acetone-d6), δ (ppm): 160.52 (C21), 153.28 (C15), 
149.06 (C3), 151.66 (C17), 145.61 (C8), 144.61 (C1), 142.49 (C7), 141.45 (C6), 139.35 (C19), 
134.43 (CorthoPPh3), 132.81 (CipsoPPh3). 131.65 (C18), 130.16 (Cmeta,paraPPh3), 127.88 (C12,13,11), 
126.07 (C20), 121.83 (C10), 121.44 (C4), 121.01 (C2), 119.91 (C5), 37.44 (C9). 
[AgL2](CF3SO3) (2) was isolated as yellow solid, 95.0 % yield. FT-IR (cm
-1): (C=N)imínic 
= 1585, (C-N)py = 1560; (CF3SO3) = 1269, 1149, 1029, 572, 516. 
19F NMR (acetone-d6), 
δ (ppm): - 80.06 (s); 1H NMR (acetone-d6), δ (ppm): 9.33 (s, H22, 2H); 8.96 (d, H17, J = 4.8 
Hz, 2H); 8.34 (d, H19, J = 7.7 Hz, 2H); 8.26 (d, H20, J = 7.0 Hz, 2H); 7-88-7.85 (m, 
H5,10,2,18, 8H); 7.64 (m, H4, 2H); 7.53 (dt, H13, J = 7.4 Hz, 2H); 7.35 (m, H11,12, 4H);  3.84 
(s, H23,24, 4H). 
13C-APT NMR (acetone-d6), δ (ppm): 159.10 (C21), 151.17 (C15), 147.60 
(C3), 152.77 (C17), 145.75 (C8), 144.71 (C1), 143.29 (C7), 141.39 (C6), 140.64 (C19), 130.29 
(C18), 129.20 (C12), 128.24 (C13), 127.89 (C11), 126.03 (C20), 123.24 (C10), 121.52 (C4), 
121.10 (C2), 119.75 (C5), 37.35 (C9). 
[AgL2](ClO4) (3) was isolated as yellow solid, 51.69 % yield. FT-IR (cm
-1): (C=N)imínic = 
1624, (C-N)py = 1589; (ClO4) =  924. 
1H NMR (acetone-d6), δ (ppm):   9.31 (s, H22, 2H); 
8.94 (s, H17, J = 4.7 Hz; 2H); 8.32 (dd, H19, J = 7.7 Hz, 2H); 8.23 (dd, H20, J = 7.7 Hz, 2H); 
7.83 (m, H5,10,2,18 ; 8H8); 7.63 (dd, H4, J = 8.1 Hz, 2H); 7.51 (d, H13, J = 7.5Hz, 2H); 7.31 
(m, H11,12, 4H); 3.82 (s, H23,24, 4H). 
13C-APT NMR  (acetone-d6), δ (ppm): 159.05 (C21), 
  
151.03 (C15), 147.51 (C3), 152.82 (C17), 145.75 (C8), 144.72 (C1), 143.33 (C7), 141.38 (C6), 
140.71 (C19), 130.51 (C18), 129.28 (C12), 128.24 (C13), 127.89 (C11), 126.03 (C20), 123.30 
(C10), 121.52 (C4), 121.11 (C2), 119.75 (C5), 37.35 (C9).  
[AgL2](BF4) (4) was isolated as yellow solid, 65.58 % yield. FT-IR (cm
-1): (C=N)imínic = 
1588, (C-N)py = 1561; (BF4) = 1007, 731, 518. 
19F NMR (acetone-d6), δ (ppm): - 153.37 
(s). 1H NMR (acetone-d6), δ (ppm): 9.20 (s, H22, 2H); 8.83 (m, H17, 2H); 8.23 (td, H19, J = 
7.7 Hz, 2H); 8.13 (dd, H20, J = 6.7 Hz, 2H);  7.72 (m, H5,10,2,18, 8H); 7.52 (dd, H4, J = 8.1 
Hz, 2H); 7.40-7.21 (m, H13,11y12, 6H); 3.71 (s, H23,24, 4H). 
13C-APT (acetone-d6), δ (ppm): 
159.07 (C21), 151.08 (C15), 147.53 (C3), 152.80 (C17), 145.75 (C8), 144.72 (C1), 143.32 
(C7), 141.38 (C6), 140.69 (C19), 130.45 (C18), 129.26 (C12), 128.24 (C13), 127.89 (C11), 
126.03 (C20), 123.28 (C10), 121.52 (C4), 121.10 (C2), 119.78 (C5), 37.35 (C9). 
[CuL2](BF4) (5) was isolated as yellow solid, 46,42 % yield. FT-IR (cm
-1): (C=N)imínic = 
1598, (C-N)py = 1582; (BF4) = 1017, 772, 514.  
19F NMR (acetone-d6), δ (ppm): - 153.37 
(s). 1H NMR (acetone-d6), δ (ppm): 9.53 (s, H22, 2H); 8.79 (s, H17, 2H); 8.31 (s, H19,20, 4H); 
7.79-7.52 (m, H5,10,2,18,4,13, 12H); 7.35 (s, H11,12, 4H); 3.82 (s, H23,24, 4H). 
13C-APT NMR 
(acetone-d6), δ (ppm): 155.60 (C21), 149.53 (C15), 148,15 (C3), 152.80 (C17), 145.82 (C8), 
144.77 (C1), 143.51 (C7), 141.31 (C6), 145.15 (C19), 128.14 (C18). 127.80 (C12), 127.35 
(C13,C11), 125.77 (C20), 121.03 (C10), 119.81 (C4), 118.99 (C5,2), 37.24 (C9). 
4.4. Crystal structure determination 
Suitable crystals for X-ray diffraction of [Ag(L)2](ClO4) (4) and [Ag(L)(PPh3)2](CF3SO3) 
(6) were grown by slow diffusion of diethyl ether into a dichloromethane solution of the 
complex 4 or 1, respectively. The crystal was mounted in inert oil on glass fibers and 
transferred to the cold gas stream of Xcalibur Oxford Diffraction diffractometer equipped 
with a low-temperature attachment. Data were collected using monochromated Mo K 
radiation (k = 0.71073 Å), scan type x. Absorption corrections based on multiple scans 
were applied with the SCALE3 ABSPACK scaling algorithm [21]. The structure was 
refined on F2 using the program SHELXL [22]. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were included using a riding model. CCDC reference 
numbers 1895607 (4) and 1895608 (6). 
4.5. Bacterial strains 
For the screening of antibacterial activity, the following strains were used: methicillin-
resistant Staphylococcus aureus (MRSA) ATCC 43300, methicillin-susceptible 
Staphylococcus aureus (MSSA) ATCC 29213, Enterococcus faecalis (E.faecalis) ATCC 
29212, Eschericha coli (E.coli) ATCC 25922, Pseudomonas aeruginosa (P.aeruginosa) 
ATCC 27853 and Klebsiella pneumoniae (K.pneumoniae) ATCC 700603. 
4.6. Antibacterial testing 
  
The Minimum Inhibitory Concentrations (MIC) was determined using a broth 
microdilution method, according to Clinical and Laboratory Standards Institute (CLSI) 
[23]. Vancomycin and gentamycin were used as quality control, according to MIC ranges 
reported by CLSI [24]. All compounds tested were dissolved in water with dimethyl 
sulfoxide (DMSO), not exceeding 1% for well. The inoculum was prepared to a turbidity 
equivalent of 0.5 McFarland standard, diluted in broth media to give a final concentration 
of 5 × 105 CFU/mL in the test tray; they were covered and placed in plastic bags to prevent 
evaporation. The plates were incubated at 35°C for 18–20 h. The MIC was defined as the 
lowest concentration of compound giving complete inhibition of visible growth. All the 
experiments were performed three times in triplicate. The MIC values for all tested 
compounds and reference drug are listed in table 1. 
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Silver(I) and Copper(I) Complexes with a Schiff Base Derived from 
2-Aminofluorene with Promising Antibacterial Activity 
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A new Schiff base was prepared by reaction of 2-aminofluorene with 2-pyridinecarboxaldehyde 
and the coordination towards silver or copper compounds studied.The biological studies showed 
that the Schiff base presents antibacterial activity in Gram-positive bacteria and E. coli and that the 
binding of silver cations largely increased this activity. 
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